Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CDC14B | O60729 | 1/20 | 0.32 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24839550 | 0.96 | CDC14B (0.32) | CDC14BCDC14AALOX5NTRK1PLK3 | |
| SCHEMBL24840127 | 0.96 | CDC14B (0.32) | CDC14BCDC14AALOX5NTRK1PLK3 | |
| SCHEMBL25578831 | 0.96 | CDC14B (0.32) | CDC14BCDC14AALOX5NTRK1PLK3 | |
| SCHEMBL25579269 | 0.95 | BACE1 (0.32) | BACE1CDC14BCDC14AALOX5NTRK1 | |
| SCHEMBL25577674 | 0.95 | BACE1 (0.33) | BACE1CDC14BCDC14AALOX5NTRK1 | |
| SCHEMBL25579361 | 0.94 | BACE1 (0.32) | BACE1CDC14BCDC14A | |
| SCHEMBL25579374 | 0.94 | BACE1 (0.33) | BACE1CDC14BCDC14AALOX5NTRK1 | |
| SCHEMBL25579392 | 0.94 | BACE1 (0.33) | BACE1CDC14BCDC14AALOX5NTRK1 | |
| SCHEMBL27017871 | 0.94 | CDC14B (0.32) | BACE1CDC14BCDC14AALOX5CA1 | |
| SCHEMBL25579466 | 0.94 | BACE1 (0.33) | BACE1CDC14BCDC14AALOX5NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, L1CAM, ESR2 | BACE1 1502/4885CDC14B 4631/4885CDC14A 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.